Evidence map›Paper›PMID 38802673›Full record

ArticleIndian journal of pediatrics2025

Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis of Second-Line Anti-Tubercular Drugs in Indian Children with Multi-Drug Resistance.

Aparna Mukherjee, Lakshminarayanan Gowtham, Sushil Kumar Kabra, Rakesh Lodha, Thirumurthy Velpandian

Abstract read
PubMed Publisher
In one paragraph

Article in Indian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aparna MukherjeeDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Lakshminarayanan GowthamOcular Pharmacology and Pharmacy Division, All India Institute of Medical Sciences, New Delhi, 110029, India.
Sushil Kumar KabraDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Rakesh LodhaDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Thirumurthy VelpandianOcular Pharmacology and Pharmacy Division, All India Institute of Medical Sciences, New Delhi, 110029, India. tvelpandian@hotmail.com.

Funding

Ministry of Health and Family Welfare (N1760/017/RS)
6 · The paper itself

Abstract

objectivesTo conduct a thorough pharmacokinetic (PK) - pharmacodynamic (PD) analysis of second-line anti-tubercular therapy (ATT) in children diagnosed with multi-drug resistant tuberculosis (MDR-TB).

methodsTwenty-seven children undergoing second-line ATT, including kanamycin (KM, n = 13), fluoroquinolones (FQs, n = 26), ethionamide (ETH, n = 20), para amino salicylic acid (PASA, n = 4), and cycloserine (CS, n = 15), were sampled at 0 (pre-dose), 1, 2, 3, and 4 h post-drug administration. Plasma drug levels were determined using a mass spectrometer and the collected dataset underwent non-compartmental PK analysis using PK solver ver2.0. PK/PD assessments involved individual drug simulation studies on 1000 subjects using Modviz Pop ver 1.0 in R-software.

resultsA total of 22 and 5 children were considered as responders and non-responders, respectively. Non-compartmental PK analysis revealed mean plasma drug levels of this study cohort attained the targeted maximum drug plasma concentration (C

conclusionsThe management of MDR-TB with second-line ATT following national guidelines had cured the majority of the children (> 80%) who participated in the study. Inter-individual variability in few children from the targeted C

Indexed as

Antitubercular AgentsTuberculosis, Multidrug-ResistantAdolescentChildChild, PreschoolCycloserineEthionamideFemaleFluoroquinolonesHumansIndiaInfantKanamycinMaleMicrobial Sensitivity TestsAntitubercular AgentsCycloserineEthionamideFluoroquinolonesKanamycinMultidrug resistant-tuberculosisPediatric populationPK/PD analysisSecond-line anti-tubercular drugsSimulation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.